A project from the American Society of Retina Specialists
Sign in to view content
Subretinal Gene Therapy Drug AGTC-501 for X-Linked Retinitis Pigmentosa: Phase 2 Randomized Controlled Masked Multicenter Clinical Trial (Skyline) Interim Safety Results
- Video
- Published 2022
Related
Category: Hereditary Retinal Disease & Genetics